Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1986 1
1987 4
1988 23
1989 21
1990 19
1991 18
1992 19
1993 38
1994 25
1995 30
1996 29
1997 35
1998 29
1999 38
2000 42
2001 39
2002 53
2003 46
2004 44
2005 58
2006 65
2007 48
2008 44
2009 51
2010 66
2011 67
2012 81
2013 86
2014 156
2015 176
2016 233
2017 223
2018 225
2019 249
2020 290
2021 314
2022 296
2023 131

Text availability

Article attribute

Article type

Publication date

Search Results

3,044 results

Results by year

Filters applied: . Clear all
Page 1
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR. Duma N, et al. Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. Mayo Clin Proc. 2019. PMID: 31378236 Review.
Lung cancer remains the leading cause of cancer deaths in the United States. ...The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest compu …
Lung cancer remains the leading cause of cancer deaths in the United States. ...The National Lung Screening Tria …
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Ettinger DS, et al. J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025. J Natl Compr Canc Netw. 2022. PMID: 35545176
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with m …
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended man …
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Molina JR, et al. Mayo Clin Proc. 2008 May;83(5):584-94. doi: 10.4065/83.5.584. Mayo Clin Proc. 2008. PMID: 18452692 Free PMC article. Review.
Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world. ...Non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States. ...
Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world. . …
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A, Abdayem P, Adjei AA, Planchard D. Desai A, et al. Lung Cancer. 2022 Jan;163:96-106. doi: 10.1016/j.lungcan.2021.12.002. Epub 2021 Dec 15. Lung Cancer. 2022. PMID: 34942494 Review.
Antibody-drug conjugates (ADCs) are rapidly establishing their place and have shown promising preliminary data in lung cancer with impressive response rates and survival outcomes in previously treated patients.There are several ADCs currently in clinical trials for …
Antibody-drug conjugates (ADCs) are rapidly establishing their place and have shown promising preliminary data in lung cancer …
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Ganti AKP, et al. J Natl Compr Canc Netw. 2021 Dec;19(12):1441-1464. doi: 10.6004/jnccn.2021.0058. J Natl Compr Canc Netw. 2021. PMID: 34902832 Free PMC article.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. ...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended mana …
Current Diagnosis and Management of Small-Cell Lung Cancer.
Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Wang S, et al. Mayo Clin Proc. 2019 Aug;94(8):1599-1622. doi: 10.1016/j.mayocp.2019.01.034. Mayo Clin Proc. 2019. PMID: 31378235 Review.
Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non-small-cell lung cancer. ...
Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics fro …
Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, Wiener RS. Gould MK, et al. Chest. 2013 May;143(5 Suppl):e93S-e120S. doi: 10.1378/chest.12-2351. Chest. 2013. PMID: 23649456 Free PMC article. Review.
METHODS: We updated prior literature reviews, synthesized evidence, and formulated recommendations by using the methods described in the "Methodology for Development of Guidelines for Lung Cancer" in the American College of Chest Physicians Lung Cancer …
METHODS: We updated prior literature reviews, synthesized evidence, and formulated recommendations by using the methods described in the "Me …
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL. Yatabe Y, et al. J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18. J Thorac Oncol. 2019. PMID: 30572031 Free PMC article.
Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical applica …
Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular t …
Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Chen R, et al. J Hematol Oncol. 2020 May 24;13(1):58. doi: 10.1186/s13045-020-00881-7. J Hematol Oncol. 2020. PMID: 32448366 Free PMC article. Review.
Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. ...
Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no …
Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis.
Li Y, Wu X, Yang P, Jiang G, Luo Y. Li Y, et al. Genomics Proteomics Bioinformatics. 2022 Oct;20(5):850-866. doi: 10.1016/j.gpb.2022.11.003. Epub 2022 Dec 1. Genomics Proteomics Bioinformatics. 2022. PMID: 36462630 Free PMC article. Review.
Machine learning-based approaches play a critical role in integrating and analyzing these large and complex datasets, which have extensively characterized lung cancer through the use of different perspectives from these accrued data. ...Moreover, we highlight the ch …
Machine learning-based approaches play a critical role in integrating and analyzing these large and complex datasets, which have extensively …
3,044 results